BREAST CANCER

You Deserve Complete Answers



CARIS® LIFE SCIENCES



Recurrence Risk May Vary Over Time

Understand Your Early and Late Distant Recurrence Risk — Right From Diagnosis

Because it is possible for breast cancer to return, it is important for patients to be armed with as much information about their own unique cancer as possible — from the very beginning.

Understanding recurrence risk in both the early (Years 0-5) and late (Years 5-15) risk windows post-diagnosis may help empower patients and care teams to make more informed, more personalized treatment decisions from the start.

Caris MI Clarity — One Test, Two Answers.

Early Risk	Late Risk
Years 0-5	Years 5-15

Caris MI Clarity™ is the first prognostic test designed to deliver insight into both early and late distant recurrence risk for postmenopausal patients with early-stage HR-positive/HER2-negative, node-negative breast cancer at the time of diagnosis. Results are typically provided to ordering physicians within three business days of receiving a tissue sample, compared to a few weeks for historical tests.

You Deserve:

- **Clarity — from the very beginning**
- **Early *and* late recurrence risk information**
- **More complete insights to inform your care decisions**

Caris believes every patient should have access to the best insights available to better inform your care plan.



Biomarker Testing Could Support Optimal Therapy Selection

Is My Biomarker Testing Comprehensive?

For patients with metastatic (Stage IV) breast cancer, comprehensive biomarker testing may help identify "errors" in cancer cells that lead to abnormal growth and spread, helping doctors learn more about the unique biology of your individual cancer. Because every breast cancer is biologically different, more complete testing matters, in order to help inform the best treatment path for you.

Get a More Complete Picture

Many labs test a selection of biomarkers, but not all labs offer comprehensive biomarker testing. For more information, visit CarisLifeSciences.com/Patients.

Ask whether your testing includes the following:	
DNA Testing	✓
RNA Testing	✓
Protein Testing	✓
All NCCN-Recommended Biomarkers*	✓

**Blood testing available for ongoing testing any time a new therapy is needed*

Genetic testing looks for inherited DNA errors that can run in families and affect disease risk, while genomic testing analyzes tumors, primarily to find treatment targets. These errors can occur in any part of your DNA or RNA, so comprehensive testing — analyzing all DNA and RNA, versus just a small subset — is helpful for guiding personalized diagnosis and treatment.

Caris maintains in-network coverage with most major commercial payers; financial assistance also is available for qualifying patients.

Two Patients, Two Paths.

Meet Jessica*



Soon after diagnosing her Stage IV breast cancer, Jessica's doctor ordered comprehensive biomarker testing, which simultaneously provided insights from DNA, RNA and protein.

What Jessica Learned:

- **Specific insights about her cancer**
- **Information about potential treatment options**
- **What questions to discuss with her doctor**



Meet Michelle*

Michelle previously had some biomarker testing, but later learned newer testing could provide more information to support her care. Her doctor agreed that more testing might be helpful.

What Michelle Learned:

- **Cancer care needs can evolve over time**
- **Different tests may provide new information**
- **It's always okay to ask whether additional testing may help**

There is No Single "Right" Path

Patients may receive testing at different times based on their personal situation, tissue availability, prior testing, individual treatment response and physician recommendations. Talk with your healthcare team about whether additional biomarker testing may be beneficial for you.

**Not real patients; for illustrative purposes only*

Additional Support and Resources for Patients

Scan to learn more, or visit CarisLifeSciences.com/Patients for more information on biomarker testing, including:

- How to find the right test for your situation
- Helpful questions to ask your doctor
- Success stories from patients like you
- Insurance coverage and financial assistance

Patient Advocacy Organizations

susan g. komen®

NBCC
NATIONAL BREAST CANCER COALITION

PRG
PINK RIBBON GOOD

LIVING BEYOND BREAST CANCER®

NCBC | NATIONAL CONSORTIUM OF BREAST CENTERS
And Interdisciplinary Cancer Care

You Deserve Clear Information

Talk with your healthcare team about whether your testing is providing the most complete picture possible.

Scan to learn more, or visit CarisLifeSciences.com/Patients.

CARIS® LIFE SCIENCES

Where Molecular Science Meets Artificial Intelligence.

©2026 Caris MPI, Inc. All rights reserved. MAT-NP-000447 10 SEP 2026